EA200800556A1 - Пептиды, используемые для лечения и диагностики аутоиммунных заболеваний - Google Patents
Пептиды, используемые для лечения и диагностики аутоиммунных заболеванийInfo
- Publication number
- EA200800556A1 EA200800556A1 EA200800556A EA200800556A EA200800556A1 EA 200800556 A1 EA200800556 A1 EA 200800556A1 EA 200800556 A EA200800556 A EA 200800556A EA 200800556 A EA200800556 A EA 200800556A EA 200800556 A1 EA200800556 A1 EA 200800556A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- diagnostics
- treatment
- autoimmune diseases
- peptides used
- autoantibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
- C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
- C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Virology (AREA)
- Obesity (AREA)
Abstract
Настоящее изобретение относится к пептидам, происходящим от антител, реагирующих с эпитопом, содержащим GPI-якорь, и к их функционально эквивалентным лигандам. Эти пептиды могут быть использованы для лечения и диагностики различных заболеваний, которые, как предполагается, вызываются нежелательным присутствием в организме аутоантител, реагирующих с эпитопами, содержащими GPI-якорь. В настоящем изобретении также описан механизм действия аутоантител, нарушающих функцию организма и вызывающих заболевание, а также способ предупреждения данного заболевания и детектирования указанного аутоантитела.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0516527A GB0516527D0 (en) | 2005-08-11 | 2005-08-11 | Peptides |
GB0609921A GB0609921D0 (en) | 2006-05-18 | 2006-05-18 | Peptides |
GB0609920A GB0609920D0 (en) | 2006-05-18 | 2006-05-18 | Peptides |
PCT/GB2006/002977 WO2007017686A2 (en) | 2005-08-11 | 2006-08-09 | Tcr-v-beta related peptides for treatment and diagnosis of autoimmune disease |
Publications (2)
Publication Number | Publication Date |
---|---|
EA200800556A1 true EA200800556A1 (ru) | 2008-10-30 |
EA015629B1 EA015629B1 (ru) | 2011-10-31 |
Family
ID=37056087
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200800556A EA015629B1 (ru) | 2005-08-11 | 2006-08-09 | Пептиды, используемые для лечения и диагностики аутоиммунных заболеваний |
Country Status (18)
Country | Link |
---|---|
US (1) | US9243062B2 (ru) |
EP (3) | EP2594591B1 (ru) |
JP (2) | JP2009505640A (ru) |
KR (2) | KR101527334B1 (ru) |
CN (1) | CN105017423B (ru) |
AU (1) | AU2006277785B2 (ru) |
BR (1) | BRPI0614366A2 (ru) |
CA (1) | CA2618796C (ru) |
CU (1) | CU23793B7 (ru) |
CY (1) | CY1120640T1 (ru) |
DK (1) | DK2594591T3 (ru) |
EA (1) | EA015629B1 (ru) |
ES (1) | ES2679994T3 (ru) |
GB (1) | GB2429013C (ru) |
HK (1) | HK1112628A1 (ru) |
IL (3) | IL189407A (ru) |
NZ (3) | NZ595386A (ru) |
WO (1) | WO2007017686A2 (ru) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
KR20180058863A (ko) | 2005-11-30 | 2018-06-01 | 애브비 인코포레이티드 | 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도 |
RU2442793C2 (ru) | 2005-11-30 | 2012-02-20 | Эбботт Лэборетриз | АНТИТЕЛА ПРОТИВ ГЛОБУЛОМЕРА Аβ, ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ЧАСТИ, СООТВЕТСТВУЮЩИЕ ГИБРИДОМЫ, НУКЛЕИНОВЫЕ КИСЛОТЫ, ВЕКТОРЫ, КЛЕТКИ-ХОЗЯЕВА, СПОСОБЫ ПОЛУЧЕНИЯ УКАЗАННЫХ АНТИТЕЛ, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ АНТИТЕЛА, ПРИМЕНЕНИЯ УКАЗАННЫХ АНТИТЕЛ И СПОСОБЫ ИСПОЛЬЗОВАНИЯ УКАЗАННЫХ АНТИТЕЛ |
US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
WO2008104386A2 (en) | 2007-02-27 | 2008-09-04 | Abbott Gmbh & Co. Kg | Method for the treatment of amyloidoses |
EP2154969B1 (en) * | 2007-05-16 | 2015-11-18 | The Brigham and Women's Hospital, Inc. | Treatment of synucleinopathies |
NZ601843A (en) * | 2007-06-12 | 2014-01-31 | Ac Immune Sa | Monoclonal anti beta amyloid antibody |
US8613923B2 (en) | 2007-06-12 | 2013-12-24 | Ac Immune S.A. | Monoclonal antibody |
US8048420B2 (en) | 2007-06-12 | 2011-11-01 | Ac Immune S.A. | Monoclonal antibody |
AU2008311367B2 (en) | 2007-10-05 | 2014-11-13 | Ac Immune S.A. | Use of anti-amyloid beta antibody in ocular diseases |
EP2352990B1 (en) * | 2008-11-05 | 2020-12-30 | Michael Himmelhaus | Method for sensing a biochemical and/or biomechanical process of a live biological cell |
ES2684475T3 (es) | 2010-04-15 | 2018-10-03 | Abbvie Inc. | Proteínas que se unen a beta amiloide |
WO2012016173A2 (en) | 2010-07-30 | 2012-02-02 | Ac Immune S.A. | Safe and functional humanized antibodies |
US9062101B2 (en) | 2010-08-14 | 2015-06-23 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
CA2811087A1 (en) * | 2010-09-29 | 2012-04-12 | Genentech, Inc. | Antibody compositions and methods of use |
JP5937106B2 (ja) * | 2011-01-20 | 2016-06-22 | サイレックス ラボラトリーズ,エルエルシー | グルテン感受性の検出およびグルテン感受性とセリアック病を鑑別するための方法ならびに装置 |
PL2855667T3 (pl) * | 2012-05-25 | 2024-03-25 | Cellectis | Sposoby uzyskiwania metodami inżynierii allogenicznych i opornych na immunosupresję limfocytów t do immunoterapii |
JP6153019B2 (ja) | 2013-01-31 | 2017-06-28 | 国立大学法人 東京大学 | リゾホスファチジルセリン受容体機能調節活性を有する化合物 |
AU2013408259B2 (en) * | 2013-12-20 | 2020-05-21 | Development Center For Biotechnology | Alpha-enolase specific antibodies and methods of uses in cancer therapy |
WO2015114576A1 (en) * | 2014-01-31 | 2015-08-06 | Universität Zürich | Use of heliocbacter pylori extract for treating or preventing inflammatory bowel diseases and coeliac disease |
JP6369721B2 (ja) | 2014-07-04 | 2018-08-08 | 国立大学法人 東京大学 | リゾホスファチジルセリン誘導体 |
GB2532426B (en) * | 2014-11-18 | 2016-11-02 | Rogers Arpi | Therapeutic homodimer and uses thereof |
US9527922B2 (en) | 2014-12-31 | 2016-12-27 | Development Center For Biotechnology | Humanized alpha-enolase specific antibodies and methods of uses in cancer therapy |
JP6585721B2 (ja) * | 2014-12-31 | 2019-10-02 | ディヴェロップメント センター フォー バイオテクノロジー | ヒト化α−エノラーゼ特異的抗体及びがん治療におけるその使用方法 |
WO2016117949A1 (ko) * | 2015-01-21 | 2016-07-28 | (의료)길의료재단 | 포스파티딜이노시톨포스페이트 결합 물질의 세포 사멸 검출 용도 |
JP6544669B1 (ja) | 2018-03-16 | 2019-07-17 | ディヴェロップメント センター フォー バイオテクノロジー | アルファエノラーゼに特異的な抗体及びその使用 |
EP3773690A1 (en) | 2018-04-13 | 2021-02-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | New vaccinal strategy |
CN110885778A (zh) * | 2018-09-07 | 2020-03-17 | 上海益诺思生物技术股份有限公司 | 从体外培养的细胞中分离Pig-a基因突变细胞的方法 |
KR20220069961A (ko) * | 2019-09-13 | 2022-05-27 | 메모리얼 슬로안 케터링 캔서 센터 | 항-cd371 항체 및 그의 용도 |
GB202015755D0 (en) * | 2020-10-05 | 2020-11-18 | Rogers Arpi | Coronavirus therapy |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
KR920701453A (ko) | 1989-03-17 | 1992-08-11 | 미리엄 디. 멕코나헤이 | 유전자발현의 외부조절 |
RU2139351C1 (ru) | 1991-04-25 | 1999-10-10 | Чугаи Сейяку Кабусики Кайся | Н- и l-цепи моноклонального антитела рм1 (монат) к рецептору il-6r человека и их v-области, модифицированная монат, его н- и l-цепи и их v-области, cdr- последовательности, днк-последовательности |
SE9102074D0 (sv) * | 1991-07-03 | 1991-07-03 | Kabi Pharmacia Ab | Tomour antigen specific antibody |
US5252479A (en) | 1991-11-08 | 1993-10-12 | Research Corporation Technologies, Inc. | Safe vector for gene therapy |
US5891623A (en) | 1992-11-09 | 1999-04-06 | Consorzio Per Le Biotecnologie | Diagnosis and treatment of AIDS onset |
GB9317423D0 (en) * | 1993-08-21 | 1993-10-06 | Imp Cancer Res Tech | Monoclonal antibodies |
US5362865A (en) | 1993-09-02 | 1994-11-08 | Monsanto Company | Enhanced expression in plants using non-translated leader sequences |
US5693506A (en) | 1993-11-16 | 1997-12-02 | The Regents Of The University Of California | Process for protein production in plants |
US6001809A (en) | 1994-07-11 | 1999-12-14 | Elan Pharmaceuticals, Inc. | Inhibitors of leukocyte adhesion |
USRE39048E1 (en) * | 1995-06-07 | 2006-03-28 | Pepscan Systems B.V. | Peptide, immunogenic composition and vaccine or medical preparation, a method to immunise animals against the hormone LHRH, and analogs of the LHRH tandem repeat peptide and their use as vaccine |
US5861260A (en) | 1996-11-05 | 1999-01-19 | University Of Massachusetts | Diagnostic methods for screening patients for scleroderma |
IL121041A0 (en) * | 1997-06-09 | 1997-11-20 | Yeda Res & Dev | Immunogenic compositions for induction of anti-tumor immunity |
CN1330754C (zh) * | 1997-07-21 | 2007-08-08 | 阿皮·马托西安-罗杰斯 | 显示针对内分泌细胞反应性的配体(包括抗体) |
DE19739685A1 (de) * | 1997-09-10 | 1999-03-11 | Eichel Streiber Christoph Von | Monoklonale Antikörper zur Therapie und Prophylaxe von Erkrankungen durch Clostridium difficile |
US7083950B2 (en) | 1998-09-25 | 2006-08-01 | Regeneron Pharmaceuticals, Inc. | High affinity fusion proteins and therapeutic and diagnostic methods for use |
US6703491B1 (en) * | 1999-03-17 | 2004-03-09 | Exelixis, Inc. | Drosophila sequences |
EP1792991A1 (en) | 1999-08-24 | 2007-06-06 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
WO2001027612A2 (de) | 1999-10-12 | 2001-04-19 | Connex Gesellschaft Zur Optimierung Von Forschung Und Entwicklung Mbh | Immunchromatographischer schnelltest zum nachweis von säure-resistenten mikroorganismen im stuhl |
EP1130032A1 (en) | 2000-02-28 | 2001-09-05 | Gesellschaft für biotechnologische Forschung mbH (GBF) | Single-chain antibodies recognizing the human vascular endothelial growth factor receptor-2 (VEGFR-2/KDR) |
GB0006398D0 (en) * | 2000-03-16 | 2000-05-03 | Novartis Ag | Organic compounds |
JP2001299349A (ja) * | 2000-04-19 | 2001-10-30 | Suntory Ltd | 新規組換え型抗体とそのcdrのアミノ酸配列およびそれをコードする遺伝子 |
CU23007A1 (es) | 2001-04-06 | 2004-12-17 | Ct De Inmunologia Molecular Ct De Inmunologia Mole | Combinaciones inmunoterapéuticas para el tratamiencombinaciones inmunoterapéuticas para el tratamiento de tumores que sobre-expresan gangliósidos to de tumores que sobre-expresan gangliósidos |
US20040115196A1 (en) * | 2001-04-18 | 2004-06-17 | Yoshiaki Fukuda | Novel recombinant antibodies, amino acid sequences of cdrs thereof and genes encoding the same |
EP2277542B1 (en) * | 2001-06-01 | 2014-04-16 | Cornell Research Foundation Inc. | Modified antibodies to prostrate-specific membrane antigen and uses thereof |
AU2002305767B2 (en) * | 2001-09-20 | 2008-04-10 | Cornell Research Foundation, Inc. | Methods and compositions for treating and preventing skin disorders using binding agents specific for PSMA |
EP1483295B1 (en) * | 2002-03-01 | 2008-12-10 | Immunomedics, Inc. | Rs7 antibodies |
US8038986B2 (en) * | 2002-07-26 | 2011-10-18 | The Walter And Eliza Hall Institute Of Medical Research | Immunogenic compositions and diagnostic and therapeutic uses thereof |
US7541440B2 (en) * | 2002-09-30 | 2009-06-02 | Immunomedics, Inc. | Chimeric, human and humanized anti-granulocyte antibodies and methods of use |
US20040136998A1 (en) | 2002-10-30 | 2004-07-15 | Bander Neil H. | Methods and compositions for treating or preventing insulin-related disorders using binding agents specific for prostate specific membrane antigen |
US20050009136A1 (en) * | 2003-02-19 | 2005-01-13 | Dyax Corporation | PAPP-A ligands |
KR100500283B1 (ko) * | 2003-03-25 | 2005-07-11 | 이뮤노믹스 주식회사 | 인간 4-1비비 분자에 대한 인간화 모노클로날 폴리펩티드 및 이를 포함하는 약학 조성물 |
EP2404615A1 (en) | 2003-04-23 | 2012-01-11 | Medarex, Inc. | Humanized antibodies to interferon alpha receptor-1 (IFNAR-1) |
CA2528182A1 (en) | 2003-06-06 | 2005-06-16 | Oncomax Acquisition Corp. | Antibodies specific for cancer associated antigen sm5-1 and uses thereof |
CA2534077A1 (en) * | 2003-07-29 | 2005-02-10 | Morphotek Inc. | Antibodies and methods for generating genetically altered antibodies with enhanced effector function |
WO2005033275A2 (en) | 2003-09-29 | 2005-04-14 | The Regents Of The University Of California | Methods for altering hematopoietic progenitor cell adhesion, differentiation, and migration |
MX337723B (es) * | 2008-12-09 | 2016-03-15 | Pfizer Vaccines Llc | Vacuna de peptido ch3 de ige. |
-
2006
- 2006-08-09 EP EP12198289.6A patent/EP2594591B1/en active Active
- 2006-08-09 KR KR1020147008188A patent/KR101527334B1/ko active IP Right Grant
- 2006-08-09 WO PCT/GB2006/002977 patent/WO2007017686A2/en active Application Filing
- 2006-08-09 CN CN201510292155.1A patent/CN105017423B/zh not_active Expired - Fee Related
- 2006-08-09 ES ES12198289.6T patent/ES2679994T3/es active Active
- 2006-08-09 EP EP06779101.2A patent/EP1919952B1/en active Active
- 2006-08-09 BR BRPI0614366-0A patent/BRPI0614366A2/pt not_active Application Discontinuation
- 2006-08-09 DK DK12198289.6T patent/DK2594591T3/en active
- 2006-08-09 EA EA200800556A patent/EA015629B1/ru not_active IP Right Cessation
- 2006-08-09 NZ NZ595386A patent/NZ595386A/xx not_active IP Right Cessation
- 2006-08-09 KR KR1020087005824A patent/KR20080039978A/ko active Application Filing
- 2006-08-09 AU AU2006277785A patent/AU2006277785B2/en not_active Ceased
- 2006-08-09 NZ NZ566245A patent/NZ566245A/en not_active IP Right Cessation
- 2006-08-09 JP JP2008525635A patent/JP2009505640A/ja active Pending
- 2006-08-09 NZ NZ595387A patent/NZ595387A/xx not_active IP Right Cessation
- 2006-08-09 US US11/990,281 patent/US9243062B2/en not_active Expired - Fee Related
- 2006-08-09 CA CA2618796A patent/CA2618796C/en not_active Expired - Fee Related
- 2006-08-09 GB GB0615831A patent/GB2429013C/en not_active Expired - Fee Related
- 2006-08-09 EP EP12198288.8A patent/EP2578602B1/en active Active
-
2008
- 2008-02-10 IL IL189407A patent/IL189407A/en not_active IP Right Cessation
- 2008-02-11 CU CU20080021A patent/CU23793B7/es active IP Right Grant
- 2008-06-17 HK HK08106624.3A patent/HK1112628A1/zh not_active IP Right Cessation
-
2012
- 2012-11-05 IL IL222879A patent/IL222879A/en not_active IP Right Cessation
- 2012-11-05 IL IL222880A patent/IL222880A/en active IP Right Grant
-
2013
- 2013-02-12 JP JP2013024857A patent/JP5738333B2/ja not_active Expired - Fee Related
-
2018
- 2018-08-16 CY CY181100863T patent/CY1120640T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA200800556A1 (ru) | Пептиды, используемые для лечения и диагностики аутоиммунных заболеваний | |
NL300919I2 (nl) | Brodalumab | |
EA200800812A1 (ru) | Композиции антитела против cd3 | |
EA201070812A1 (ru) | Лечение и профилактика амилоидоза | |
EA201001874A1 (ru) | Способ диагностики злокачественных новообразований, экспрессирующих рецептор her2 или его укороченные варианты | |
EA202092933A1 (ru) | Антитела к entpd2, виды комбинированной терапии и способы применения антител и видов комбинированной терапии | |
CO6400231A2 (es) | Proteínas de unión a il-1 | |
EA201990004A1 (ru) | АНТИ-IgE АНТИТЕЛА | |
EA201692192A1 (ru) | СВЯЗЫВАЮЩЕЕСЯ С FcRn АНТИТЕЛО ДЛЯ ЛЕЧЕНИЯ АУТОИММУННЫХ ЗАБОЛЕВАНИЙ | |
EA200901436A1 (ru) | Антигенсвязывающие белки, связывающие par-2 | |
EA201171397A1 (ru) | Иммунологическое нацеливание на патологические тау-протеины | |
AR084210A1 (es) | PROTEINAS DE UNION AL TNF-a | |
WO2006084226A3 (en) | Antibodies that bind to epha2 and methods of use thereof | |
EA201490677A1 (ru) | Связывающие антиген cd27l белки | |
MX2009012949A (es) | Anticuerpos humanizados que enlazan a ab (1-42) globulomero y usos de los mismos. | |
EA201270813A1 (ru) | АНТИТЕЛА К N3pGlu БЕТА-АМИЛОИДНОМУ ПЕПТИДУ И ИХ ПРИМЕНЕНИЕ | |
MX338940B (es) | Identificacion de epitopos ige novedosos. | |
EA201070539A1 (ru) | НОВЫЕ АНТИТЕЛА, СПЕЦИФИЧНЫЕ К β-АМИЛОИДНЫМ ПЕПТИДАМ, И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ДИАГНОСТИЧЕСКИХ ИЛИ ЛЕКАРСТВЕННЫХ СРЕДСТВ | |
EA201001335A1 (ru) | Антитела, направленные против ангиопоэтина-1 и ангиопоэтина-2, и их применение | |
WO2006084078A3 (en) | Jam-3 and antibodies that bind thereto | |
EP2386577A3 (en) | Tumor-targeting monoclonal antibodies to FZD10 and uses thereof | |
RU2017129721A (ru) | АНТИТЕЛА ПРОТИВ αβTCR | |
WO2006083852A3 (en) | Luca2 and antibodies that bind thereto | |
EA201590187A1 (ru) | Моноклональные антитела для применения в диагностике и терапии злокачественных опухолей и аутоиммунного заболевания | |
WO2006076584A3 (en) | Kid31 and antibodies that bind thereto |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): KG MD TJ |
|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): KZ TM |
|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AZ BY |